Last reviewed · How we verify
Bone Marrow Aspirate Injection
Bone marrow aspirate injection delivers autologous bone marrow-derived cells to promote tissue regeneration and repair through paracrine signaling and stem cell differentiation.
Bone marrow aspirate injection delivers autologous bone marrow-derived cells to promote tissue regeneration and repair through paracrine signaling and stem cell differentiation. Used for Tissue regeneration and repair (specific indication under investigation in Phase 3 trial).
At a glance
| Generic name | Bone Marrow Aspirate Injection |
|---|---|
| Also known as | BMA, BM aspirate |
| Sponsor | Federal University of São Paulo |
| Drug class | Cell therapy |
| Modality | Biologic |
| Therapeutic area | Regenerative Medicine |
| Phase | Phase 3 |
Mechanism of action
The procedure involves harvesting bone marrow from the patient, processing it to concentrate mononuclear cells and progenitor cells, and injecting the aspirate directly into damaged or diseased tissue. These cells secrete growth factors and cytokines that reduce inflammation, promote angiogenesis, and stimulate endogenous repair mechanisms. The autologous nature minimizes immunological rejection while leveraging the regenerative potential of bone marrow stem cells.
Approved indications
- Tissue regeneration and repair (specific indication under investigation in Phase 3 trial)
Common side effects
- Injection site pain or discomfort
- Infection at injection site
- Bleeding or hematoma
- Bone marrow harvest site pain
Key clinical trials
- AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration
- Bone Marrow Aspirate Concentrate Versus Triamcinolone Injection For Hip Osteoarthritis (PHASE3)
- Orthobiological Therapies in Musculoskeletal Disorders (EARLY_PHASE1)
- Bone Marrow Versus Adipose Tissue as a Cell Source for Infiltrative Treatment of Knee Osteoarthritis (NA)
- Biologic Injection For Adults With Lumbar Disc Herniation (NA)
- Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation (PHASE1)
- Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes (PHASE2)
- Autologous BMA vs Saline and LAM + LP-PRP vs Saline Evaluations in Knee OA (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |